Pharmacist-led chronic disease management: A systematic review of effectiveness and harms compared with usual care

Annals of Internal Medicine

Volumn 165, Issue 1, 2016, Pages 30-40

  Greer, Nancy ^a   Bolduc, Jennifer ^a   Geurkink, Eric ^a   Rector, Thomas ^a   Olson, Kimberly ^a   Koeller, Eva ^a   MacDonald, Roderick ^a   Wilt, Timothy J ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE MANAGEMENT; DYSLIPIDEMIA; EMERGENCY WARD; GOAL ATTAINMENT; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; MEDICATION COMPLIANCE; MORTALITY; PATIENT SATISFACTION; PHARMACIST; POLYPHARMACY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 84978033571     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-3058     Document Type: Review

References (83)

1. H.R. 592-Pharmacy and Medically Underserved Areas Enhancement Act, 114th Congress (2015-2016). Accessed at www.congress .gov/bill/114th-congress/house-bill/592 on 20 November 2015.
2. S.314-Pharmacy and Medically Underserved Areas Enhancement Act, 114th Congress (2015-2016). Accessed at www.congress.gov/bill/114th-congress/senate-bill/314, on 20 November 2015.
3. Hepler CD. The third wave in pharmaceutical education: the clinical movement. Am J Pharm Educ. 1987;51:369-85. [PMID: 10302396]
4. Clause S, Fudin J, Mergner A, Lutz JL, Kavanaugh MM, Fessler K, et al. Prescribing privileges among pharmacists in Veterans affairs medical centers. Am J Health Syst Pharm. 2001;58:1143-5. [PMID: 11449859]
5. Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker- Schwimmer E, Posey R, et al. Medication therapy management interventions in outpatient settings: a systematic review and metaanalysis. JAMA Intern Med. 2015;175:76-87. [PMID: 25401788] doi: 10.1001/jamainternmed.2014.5841
6. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. v 5.1.0 [updated March, 2011]. The Cochrane Collaboration; 2011. Accessed at www.cochrane-handbook.org on 11 December 2015.
7. Owens DK, Lohr KN, Atkins D, Treadwell JR, Reston JT, Bass EB, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions-Agency for Healthcare Research and Quality and the effective health-care program. J Clin Epidemiol. 2010;63:513-23. [PMID: 19595577] doi:10.1016/j .jclinepi.2009.03.009
8. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60. [PMID: 12958120]
9. Taveira TH, Wu WC. Interventions to maintain cardiac risk control after discharge from a cardiovascular risk reduction clinic: a randomized controlled trial. Diabetes Res Clin Pract. 2014;105:327-35. [PMID: 24969964] doi:10.1016/j.diabres.2014.05.013
10. Irons BK, Meyerrose G, Laguardia S, Hazel K, Seifert CF. A collaborative cardiologist-pharmacist care model to improve hypertension management in patients with or at high risk for cardiovascular disease. Pharm Pract (Granada). 2012;10:25-32. [PMID: 24155813]
11. Spence MM, Makarem AF, Reyes SL, Rosa LL, Nguyen C, Oyekan EA, et al. Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease. J Manag Care Spec Pharm. 2014;20:1036-45. [PMID: 25278326]
12. Olson KL, Delate T, Rasmussen J, Humphries TL, Merenich JA; Clinical Pharmacy Cardiac Risk Service Study Group. Outcomes of patients discharged from pharmacy-managed cardiovascular disease management. Am J Manag Care. 2009;15:497-503. [PMID: 19670953]
13. Gattis WA, Hasselblad V, Whellan DJ, OConnor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) Study. Arch Intern Med. 1999;159:1939-45. [PMID: 10493325]
14. Murray MD, Young J, Hoke S, Tu W, Weiner M, Morrow D, et al. Pharmacist intervention to improve medication adherence in heart failure: a randomized trial. Ann Intern Med. 2007;146:714-25. [PMID: 17502632]
15. Pai AB, Boyd A, Chavez A, Manley HJ. Health-related quality of life is maintained in hemodialysis patients receiving pharmaceutical care: a 2-year randomized, controlled study. Hemodial Int. 2009;13: 72-9. [PMID: 19210281] doi:10.1111/j.1542-4758.2009.00328.x
16. Pai AB, Boyd A, Depczynski J, Chavez IM, Khan N, Manley H. Reduced drug use and hospitalization rates in patients undergoing hemodialysis who received pharmaceutical care: a 2-year, randomized, controlled study. Pharmacotherapy. 2009;29:1433-40. [PMID: 19947803] doi:10.1592/phco.29.12.1433
17. Bucaloiu ID, Akers G, Bermudez MC, Mainali R, Brown BL, Roberts SS, et al. Outpatient erythropoietin administered through a protocol-driven, pharmacist-managed program may produce significant patient and economic benefits. Manag Care Interface. 2007;20: 26-30. [PMID: 17708080]
18. Cooney D, Moon H, Liu Y, Miller RT, Perzynski A, Watts B, et al. A pharmacist based intervention to improve the care of patients with CKD: a pragmatic, randomized, controlled trial. BMC Nephrol. 2015; 16:56. [PMID: 25881226] doi:10.1186/s12882-015-0052-2
19. Aspinall SL, Cunningham FE, Zhao X, Boresi JS, Tonnu-Mihara IQ, Smith KJ, et al. ESA Clinic Study Group. Impact of pharmacistmanaged erythropoiesis-stimulating agents clinics for patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2012;60:371-9. [PMID: 22633556] doi:10.1053/j.ajkd.2012.04.013
20. Aspinall SL, Smith KJ, Good CB, Zhao X, Stone RA, Tonnu- Mihara IQ, et al. Incremental cost effectiveness of pharmacistmanaged erythropoiesis-stimulating agent clinics for non-dialysisdependent chronic kidney disease patients. Appl Health Econ Health Policy. 2013;11:653-60. [PMID: 24092553] doi:10.1007/s40258-013 -0057-6
21. Solomon DK, Portner TS, Bass GE, Gourley DR, Gourley GA, Holt JM, et al. Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998;38:574-85. [PMID: 9782691]
22. Gourley GA, Portner TS, Gourley DR, Rigolosi EL, Holt JM, Solomon DK, et al. Humanistic outcomes in the hypertension and COPD arms of a multicenter outcomes study. J Am Pharm Assoc (Wash). 1998;38:586-97. [PMID: 9782692]
23. Adler DA, Bungay KM, Wilson IB, Pei Y, Supran S, Peckham E, et al. The impact of a pharmacist intervention on 6-month outcomes in depressed primary care patients. Gen Hosp Psychiatry. 2004;26: 199-209. [PMID: 15121348]
24. Capoccia KL, Boudreau DM, Blough DK, Ellsworth AJ, Clark DR, Stevens NG, et al. Randomized trial of pharmacist interventions to improve depression care and outcomes in primary care. Am J Health Syst Pharm. 2004;61:364-72. [PMID: 15011764]
25. Boudreau DM, Capoccia KL, Sullivan SD, Blough DK, Ellsworth AJ, Clark DL, et al. Collaborative care model to improve outcomes in major depression. Ann Pharmacother. 2002;36:585-91. [PMID: 11918503]
26. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, et al. Impact of a collaborative care model on depression in a primary care setting: a randomized controlled trial. Pharmacotherapy. 2003;23: 1175-85. [PMID: 14524649]
27. Finley PR, Rens HR, Pont JT, Gess SL, Louie C, Bull SA, et al. Impact of a collaborative pharmacy practice model on the treatment of depression in primary care. Am J Health Syst Pharm. 2002;59: 1518-26. [PMID: 12185826]
28. Taveira TH, Dooley AG, Cohen LB, Khatana SA, Wu WC. Pharmacist-led group medical appointments for the management of type 2 diabetes with comorbid depression in older adults. Ann Pharmacother. 2011;45:1346-55. [PMID: 22028418] doi:10.1345/aph .1Q212
29. Taveira TH, Friedmann PD, Cohen LB, Dooley AG, Khatana SA, Pirraglia PA, et al. Pharmacist-led group medical appointment model in type 2 diabetes. Diabetes Educ. 2010;36:109-17. [PMID: 19966072] doi:10.1177/0145721709352383
30. Cohen LB, Taveira TH, Khatana SA, Dooley AG, Pirraglia PA, Wu WC. Pharmacist-led shared medical appointments for multiple cardiovascular risk reduction in patients with type 2 diabetes. Diabetes Educ. 2011;37:801-12. [PMID: 22021025] doi:10.1177/01457 21711423980
31. Heisler M, Hofer TP, Klamerus ML, Schmittdiel J, Selby J, Hogan MM, et al. Study protocol: the Adherence and Intensification of Medications (AIM) study-a cluster randomized controlled effectiveness study. Trials. 2010;11:95. [PMID: 20939913] doi:10.1186/1745 -6215-11-95
32. Heisler M, Hofer TP, Schmittdiel JA, Selby JV, Klamerus ML, Bosworth HB, et al. Improving blood pressure control through a clinical pharmacist outreach program in patients with diabetes mellitus in 2 high-performing health systems: the adherence and intensification of medications cluster randomized, controlled pragmatic trial. Circulation. 2012;125:2863-72. [PMID: 22570370] doi:10.1161/CIRCULATIONAHA.111.089169
33. Skinner JS, Poe B, Hopper R, Boyer A, Wilkins CH. Assessing the effectiveness of pharmacist-directed medication therapy management in improving diabetes outcomes in patients with poorly controlled diabetes. Diabetes Educ. 2015;41:459-65. [PMID: 26009557] doi:10.1177/0145721715587563
34. Jameson JP, Baty PJ. Pharmacist collaborative management of poorly controlled diabetes mellitus: a randomized controlled trial. Am J Manag Care. 2010;16:250-5. [PMID: 20394460]
35. Jaber LA, Halapy H, Fernet M, Tummalapalli S, Diwakaran H. Evaluation of a pharmaceutical care model on diabetes management. Ann Pharmacother. 1996;30:238-43. [PMID: 8833557]
36. Jacobs M, Sherry PS, Taylor LM, Amato M, Tataronis GR, Cushing G. Pharmacist Assisted Medication Program Enhancing the Regulation of Diabetes (PAMPERED) study. J Am Pharm Assoc (2003). 2012;52:613-21. [PMID: 23023841]
37. Rothman RL, Malone R, Bryant B, Shintani AK, Crigler B, Dewalt DA, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005; 118:276-84. [PMID: 15745726]
38. Scott DM, Boyd ST, Stephan M, Augustine SC, Reardon TP. Outcomes of pharmacist-managed diabetes care services in a community health center. Am J Health Syst Pharm. 2006;63:2116-22. [PMID: 17057049]
39. Shane-McWhorter L, Oderda GM. Providing diabetes education and care to underserved patients in a collaborative practice at a Utah community health center. Pharmacotherapy. 2005;25:96-109. [PMID: 15767225]
40. Johnson KA, Chen S, Cheng IN, Lou M, Gregerson P, Blieden C, et al. The impact of clinical pharmacy services integrated into medical homes on diabetes-related clinical outcomes. Ann Pharmacother. 2010;44:1877-86. [PMID: 21119101] doi:10.1345/aph.1P380
41. Ip EJ, Shah BM, Yu J, Chan J, Nguyen LT, Bhatt DC. Enhancing diabetes care by adding a pharmacist to the primary care team. Am J Health Syst Pharm. 2013;70:877-86. [PMID: 23640349] doi:10 .2146/ajhp120238
42. Kelly C, Rodgers PT. Implementation and evaluation of a pharmacist-managed diabetes service. J Manag Care Pharm. 2000; 6:488-493.
43. Padiyara RS, DSouza JJ, Rihani RS. Clinical pharmacist intervention and the proportion of diabetes patients attaining prevention objectives in a multispecialty medical group. J Manag Care Pharm. 2011;17:456-62. [PMID: 21787031]
44. Brummel AR, Soliman AM, Carlson AM, de Oliveira DR. Optimal diabetes care outcomes following face-to-face medication therapy management services. Popul Health Manag. 2013;16:28-34. [PMID: 23113628] doi:10.1089/pop.2012.0023
45. Fox D, Ried LD, Klein GE, Myers W, Foli K. A medication therapy management program's impact on low-density lipoprotein cholesterol goal attainment in Medicare Part D patients with diabetes. J Am Pharm Assoc (2003). 2009;49:192-9. [PMID: 19289345] doi:10.1331/JAPhA.2009.09016
46. Pape GA, Hunt JS, Butler KL, Siemienczuk J, LeBlanc BH, Gillanders W, et al. Team-based care approach to cholesterol management in diabetes mellitus: two-year cluster randomized controlled trial. Arch Intern Med. 2011;171:1480-6. [PMID: 21911633] doi:10.1001/archinternmed.2011.417
47. Salvo MC, Brooks AM. Glycemic control and preventive care measures of indigent diabetes patients within a pharmacistmanaged insulin titration program vs standard care. Ann Pharmacother. 2012;46:29-34. [PMID: 22202497] doi:10.1345/aph.1Q512
48. Chung N, Rascati K, Lopez D, Jokerst J, Garza A. Impact of a clinical pharmacy program on changes in hemoglobin A1c, diabetes-related hospitalizations, and diabetes-related emergency department visits for patients with diabetes in an underserved population. J Manag Care Spec Pharm. 2014;20:914-9. [PMID: 25166290]
49. Odegard PS, Goo A, Hummel J, Williams KL, Gray SL. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005;39:433-40. [PMID: 15701763]
50. Stroup J, Kane MP, Busch RS, Bakst G, Hamilton RA. The diabetes home visitation program. Am J Pharm Educ. 2003;67:1-4.
51. McAdam-Marx C, Dahal A, Jennings B, Singhal M, Gunning K. The effect of a diabetes collaborative care management program on clinical and economic outcomes in patients with type 2 diabetes. J Manag Care Spec Pharm. 2015;21:452-68. [PMID: 26011547]
52. Smith MC, Boldt AS, Walston CM, Zillich AJ. Effectiveness of a pharmacy care management program for veterans with dyslipidemia. Pharmacotherapy. 2013;33:736-43. [PMID: 23625745] doi:10 .1002/phar.1273
53. Miller AE, Hansen LB, Saseen JJ. Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients. Pharmacotherapy. 2008; 28:553-61. [PMID: 18447653] doi:10.1592/phco.28.5.553
54. Mazzolini TA, Irons BK, Schell EC, Seifert CF. Lipid levels and use of lipid-lowering drugs for patients in pharmacist-managed lipid clinics versus usual care in 2 VA Medical Centers. J Manag Care Pharm. 2005;11:763-71. [PMID: 16300420]
55. Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy. 2005;25:360-71. [PMID: 15843283]
56. Ellis SL, Carter BL, Malone DC, Billups SJ, Okano GJ, Valuck RJ, et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1508-16. [PMID: 11130223]
57. Bogden PE, Koontz LM, Williamson P, Abbott RD. The physician and pharmacist team. An effective approach to cholesterol reduction. J Gen Intern Med. 1997;12:158-64. [PMID: 9100140]
58. Konzem SL, Gray DR, Kashyap ML. Effect of pharmaceutical care on optimum colestipol treatment in elderly hypercholesterolemic veterans. Pharmacotherapy. 1997;17:576-83. [PMID: 9165562]
59. Carter BL, Coffey CS, Ardery G, Uribe L, Ecklund D, James P, et al. Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. Circ Cardiovasc Qual Outcomes. 2015;8:235-43. [PMID: 25805647] doi:10.1161/CIRCOUTCOMES.114.001283
60. Gums TH, Uribe L, Vander Weg MW, James P, Coffey C, Carter BL. Pharmacist intervention for blood pressure control: medication intensification and adherence. J Am Soc Hypertens. 2015;9:569-78. [PMID: 26077795] doi:10.1016/j.jash.2015.05.005
61. Polgreen LA, Han J, Carter BL, Ardery GP, Coffey CS, Chrischilles EA, et al. Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. Hypertension. 2015; 66:1145-51.[PMID:26527048]doi:10.1161/HYPERTENSIONAHA.115 .06023
62. Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013;310:46-56. [PMID: 23821088] doi: 10.1001/jama.2013.6549
63. Carter BL, Ardery G, Dawson JD, James PA, Bergus GR, Doucette WR, et al. Physician and pharmacist collaboration to improve blood pressure control. Arch Intern Med. 2009;169:1996-2002. [PMID: 19933962] doi:10.1001/archinternmed.2009.358
64. Carter BL, Bergus GR, Dawson JD, Farris KB, Doucette WR, Chrischilles EA, et al. A cluster randomized trial to evaluate physician/ pharmacist collaboration to improve blood pressure control. J Clin Hypertens (Greenwich). 2008;10:260-71. [PMID: 18401223]
65. Erickson SR, Slaughter R, Halapy H. Pharmacists' ability to influence outcomes of hypertension therapy. Pharmacotherapy. 1997; 17:140-7. [PMID: 9017775]
66. Zillich AJ, Jaynes HA, Bex SD, Boldt AS, Walston CM, Ramsey DC, et al. Evaluation of pharmacist care for hypertension in the Veterans Affairs patient-centered medical home: a retrospective casecontrol study. Am J Med. 2015;128:539.e1-6. [PMID: 25534422] doi: 10.1016/j.amjmed.2014.11.027
67. Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011;17:e96-103. [PMID: 21774100]
68. Vivian EM. Improving blood pressure control in a pharmacistmanaged hypertension clinic. Pharmacotherapy. 2002;22:1533-40. [PMID: 12495164]
69. Hirsch JD, Steers N, Adler DS, Kuo GM, Morello CM, Lang M, et al. Primary care-based, pharmacist-physician collaborative medication-therapy management of hypertension: a randomized, pragmatic trial. Clin Ther. 2014;36:1244-54. [PMID: 25085406] doi: 10.1016/j.clinthera.2014.06.030
70. Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA. A pharmacist-led, American Heart Association Heart360 Webenabled home blood pressure monitoring program. Circ Cardiovasc Qual Outcomes. 2013;6:157-63. [PMID: 23463811] doi:10.1161/CIRCOUTCOMES.112.968172
71. Green BB, Cook AJ, Ralston JD, Fishman PA, Catz SL, Carlson J, et al. Effectiveness of home blood pressure monitoring, Web communication, and pharmacist care on hypertension control: a randomized controlled trial.JAMA.2008;299:2857-67. [PMID:18577730]doi: 10.1001/jama.299.24.2857
72. Hunt JS, Siemienczuk J, Pape G, Rozenfeld Y, MacKay J, LeBlanc BH, et al. A randomized controlled trial of team-based care: impact of physician-pharmacist collaboration on uncontrolled hypertension. J Gen Intern Med. 2008;23:1966-72. [PMID: 18815843] doi:10.1007/s11606-008-0791-x
73. Borenstein JE, Graber G, Saltiel E, Wallace J, Ryu S, Archi J, et al. Physician-pharmacist comanagement of hypertension: a randomized, comparative trial. Pharmacotherapy. 2003;23:209-16. [PMID: 12587810]
74. Ralston JD, Cook AJ, Anderson ML, Catz SL, Fishman PA, Carlson J, et al. Home blood pressure monitoring, secure electronic messaging and medication intensification for improving hypertension control: a mediation analysis. Appl Clin Inform. 2014;5:232-48. [PMID: 24734136] doi:10.4338/ACI-2013-10-RA-0079
75. Okamoto MP, Nakahiro RK. Pharmacoeconomic evaluation of a pharmacist-managed hypertension clinic. Pharmacotherapy. 2001; 21:1337-44. [PMID: 11714206]
76. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and lowdensity lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2563-71. [PMID: 17101639]
77. Taylor CT, Byrd DC, Krueger K. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm. 2003; 60:1123-9. [PMID: 12816022]
78. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. An economic analysis of a randomized, controlled, multicenter study of clinical pharmacist interventions for high-risk veterans: the IMPROVE study. Impact of Managed Pharmaceutical Care Resource Utilization and Outcomes in Veterans Affairs Medical Centers. Pharmacotherapy. 2000;20:1149-58. [PMID: 11034037]
79. Malone DC, Carter BL, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Can clinical pharmacists affect SF-36 scores in veterans at high risk for medication-related problems? Med Care. 2001;39:113-22. [PMID: 11176549]
80. Kulchaitanaroaj P, Brooks JM, Ardery G, Newman D, Carter BL. Incremental costs associated with physician and pharmacist collaboration to improve blood pressure control. Pharmacotherapy. 2012; 32:772-80. [PMID: 23307525] doi:10.1002/j.1875-9114.2012 .01103.x
81. Shane-McWhorter L, McAdam-Marx C, Lenert L, Petersen M, Woolsey S, Coursey JM, et al. Pharmacist-provided diabetes management and education via a telemonitoring program. J Am Pharm Assoc(2003). 2015;55:516-26. [PMID:26359961]doi:10.1331/JAPhA .2015.14285
82. Santschi V, Chiolero A, Colosimo AL, Platt RW, Taffe P, Burnier M, et al. Improving blood pressure control through pharmacist interventions: a meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3:e000718. [PMID: 24721801] doi:10.1161/JAHA.113 .000718
83. Chisholm-Burns MA, Kim Lee J, Spivey CA, Slack M, Herrier RN, Hall-Lipsy E, et al. US pharmacists' effect as team members on patient care: systematic review and meta-analyses. Med Care. 2010;48: 923-933. [PMID: 20720510] doi:10.1097/MLR.0b013e3181e57962